skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Index

Are Drug Companies Living Up to Their Human Rights Responsibilities? Moving Toward Assessment

Gruskin, Sofia ; Raad, Zyde

PLoS Medicine, 2010, Vol.7(9), p.e1000310 [Peer Reviewed Journal]

Full text available

View all versions
Citations Cited by
  • Title:
    Are Drug Companies Living Up to Their Human Rights Responsibilities? Moving Toward Assessment
  • Author: Gruskin, Sofia ; Raad, Zyde
  • Description: As one viewpoint of three in the PLoS Medicine Debate on whether drug companies are living up to their human rights responsibilities, Sofia Gruskin and Zyde Raad argue that companies' actions to promote access to medicines, including their interactions with state and non-state actors, must be better monitored. ; The human rights responsibilities of drug companies have been considered for years by nongovernmental organizations, but were most sharply defined in a report by the UN Special Rapporteur on the right to health, submitted to the United Nations General Assembly in August 2008. The “Human Rights Guidelines for Pharmaceutical Companies in relation to Access to Medicines” include responsibilities for transparency, management, monitoring and accountability, pricing, and ethical marketing, and against lobbying for more protection in intellectual property laws, applying for patents for trivial modifications of existing medicines, inappropriate drug promotion, and excessive pricing. Two years after the release of the Guidelines, the Debate asks whether drug companies are living up to their human rights responsibilities. Sofia Gruskin and Zyde Raad from the Harvard School of Public Health say more assessment is needed of such responsibilities; Geralyn Ritter, Vice President of Global Public Policy and Corporate Responsibility at Merck & Co. argues that multiple stakeholders could do more to help States deliver the right to health; and Paul Hunt and Rajat Khosla introduce Mr. Hunt's work as the UN Special Rapporteur on the right to the highest attainable standard of health, regarding the human rights responsibilities of pharmaceutical companies and access to medicines.
  • Is Part Of: PLoS Medicine, 2010, Vol.7(9), p.e1000310
  • Identifier: E-ISSN: 1549-1676 ; DOI: 10.1371/journal.pmed.1000310
  • Subjects: The Plos Medicine Debate ; Public Health And Epidemiology -- Global Health ; Public Health And Epidemiology -- Health Policy ; Public Health And Epidemiology -- Health Services Research And Economics
  • Language: English

Searching Remote Databases, Please Wait